This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
While the FDA’s diversity guidance for clinical trials has been temporarily rest...
After its potential kidney disease drug went down in flames late last year, Novo...
It’s unclear how many staff at the FDA have been affected. There have also been ...
It’s unclear how many staff at the FDA have been affected. There have also been ...
The National Institutes of Health has lost two distinguished leaders as mass lay...
J&J said it found no immediate procedure-related causes from the atrial fibrilla...
Septerna stood out from the crowd of biotech IPOs last year due to the lack of c...
Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfro...
Gilead Sciences has defied analysts’ expectations by passing on its chance to li...
Solid Biosciences has surged back into the Duchenne muscular dystrophy gene ther...
Gilead Sciences has defied analysts’ expectations by passing on its chance to li...
Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason...
Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason...
Corbus Pharmaceuticals has posted the first Western clinical data on its would-b...
The company’s randomized clinical trial, published in Nature Medicine, tested th...
Renee Wegrzyn, Ph.D., the inaugural head of the Advanced Research Projects Agenc...
Nearly one million people in the U.S. and more than six million people worldwide...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Boston biotech Kojin Therapeutics is closing its doors, citing four funding chal...
The company’s randomized clinical trial, published in Nature Medicine, tested th...
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...
Bambusa Therapeutics has raised about $90 million to build out a pipeline of nex...
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts ha...
After its depression candidate failed a phase 3 trial and disappointed analysts,...